BR112022019508A2 - Moduladores de mtorc1 e seus usos - Google Patents

Moduladores de mtorc1 e seus usos

Info

Publication number
BR112022019508A2
BR112022019508A2 BR112022019508A BR112022019508A BR112022019508A2 BR 112022019508 A2 BR112022019508 A2 BR 112022019508A2 BR 112022019508 A BR112022019508 A BR 112022019508A BR 112022019508 A BR112022019508 A BR 112022019508A BR 112022019508 A2 BR112022019508 A2 BR 112022019508A2
Authority
BR
Brazil
Prior art keywords
mtorc1
modulators
diseases
salts
treatment
Prior art date
Application number
BR112022019508A
Other languages
English (en)
Inventor
John Kincaid
Original Assignee
Aeovian Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeovian Pharmaceuticals Inc filed Critical Aeovian Pharmaceuticals Inc
Publication of BR112022019508A2 publication Critical patent/BR112022019508A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Burglar Alarm Systems (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

MODULADORES DE mTORC1 E SEUS USOS. A descrição provê compostos e sais que mostram alta seletividade e atividade inibidora para mTORC1 e seus usos para o tratamento de doenças.
BR112022019508A 2020-03-27 2021-03-26 Moduladores de mtorc1 e seus usos BR112022019508A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063001144P 2020-03-27 2020-03-27
US202063001177P 2020-03-27 2020-03-27
US202063001187P 2020-03-27 2020-03-27
US202063019176P 2020-05-01 2020-05-01
US202063054763P 2020-07-21 2020-07-21
US202063054768P 2020-07-21 2020-07-21
US202063054762P 2020-07-21 2020-07-21
PCT/US2021/024536 WO2021195599A1 (en) 2020-03-27 2021-03-26 Mtorc1 modulators and uses thereof

Publications (1)

Publication Number Publication Date
BR112022019508A2 true BR112022019508A2 (pt) 2022-11-16

Family

ID=77892684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019508A BR112022019508A2 (pt) 2020-03-27 2021-03-26 Moduladores de mtorc1 e seus usos

Country Status (12)

Country Link
US (3) US11634432B2 (pt)
EP (1) EP4126229A4 (pt)
JP (1) JP2023530778A (pt)
KR (1) KR20230084095A (pt)
CN (1) CN115776907A (pt)
AU (1) AU2021241718A1 (pt)
BR (1) BR112022019508A2 (pt)
CA (1) CA3173722A1 (pt)
IL (1) IL296828A (pt)
MX (1) MX2022011964A (pt)
WO (1) WO2021195599A1 (pt)
ZA (1) ZA202210888B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
GB2586764B (en) 2019-01-22 2022-02-09 Aeovian Pharmaceuticals Inc MTORC modulators and uses thereof
MX2022006807A (es) 2019-12-05 2022-09-12 Anakuria Therapeutics Inc Análogos de rapamicina y usos de estos.
BR112022019508A2 (pt) 2020-03-27 2022-11-16 Aeovian Pharmaceuticals Inc Moduladores de mtorc1 e seus usos
CN116322677A (zh) * 2020-07-21 2023-06-23 艾奥维安制药公司 Mtorc1调节剂及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US6187757B1 (en) * 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
ES2219388T3 (es) * 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
CA2612829A1 (en) 2005-06-22 2006-12-28 Lifecycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
EP2675450B1 (en) * 2011-02-16 2016-02-10 Novartis AG Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
US20160138027A1 (en) * 2013-03-14 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
EP3811970A1 (en) * 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
JP6692798B2 (ja) 2014-09-11 2020-05-13 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ｍＴＯＲＣ１阻害剤
JP6793652B2 (ja) 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108926533B (zh) 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
US10478561B2 (en) 2017-08-03 2019-11-19 Minhong Yu Wireless transmission system with integrated sensing capability
UY37900A (es) * 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
KR20210105397A (ko) 2018-12-18 2021-08-26 노파르티스 아게 라파마이신 유도체
GB2586764B (en) 2019-01-22 2022-02-09 Aeovian Pharmaceuticals Inc MTORC modulators and uses thereof
MX2022006807A (es) 2019-12-05 2022-09-12 Anakuria Therapeutics Inc Análogos de rapamicina y usos de estos.
BR112022019508A2 (pt) 2020-03-27 2022-11-16 Aeovian Pharmaceuticals Inc Moduladores de mtorc1 e seus usos
CN116322677A (zh) 2020-07-21 2023-06-23 艾奥维安制药公司 Mtorc1调节剂及其用途
BR112023014287A2 (pt) 2021-01-22 2023-11-21 Janssen Pharmaceutica Nv Análogos de rapamicina e usos dos mesmos

Also Published As

Publication number Publication date
MX2022011964A (es) 2022-12-02
KR20230084095A (ko) 2023-06-12
ZA202210888B (en) 2024-02-28
AU2021241718A1 (en) 2022-10-20
US11603377B2 (en) 2023-03-14
JP2023530778A (ja) 2023-07-19
US20220332727A1 (en) 2022-10-20
US20220235069A1 (en) 2022-07-28
WO2021195599A1 (en) 2021-09-30
US20240002399A1 (en) 2024-01-04
IL296828A (en) 2022-11-01
CA3173722A1 (en) 2021-09-30
CN115776907A (zh) 2023-03-10
US11634432B2 (en) 2023-04-25
EP4126229A1 (en) 2023-02-08
EP4126229A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
BR112022019508A2 (pt) Moduladores de mtorc1 e seus usos
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
BR112018000635A2 (pt) compostos aza substituídos como inibidores irak-4
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
BR112016024533A8 (pt) derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
CL2019001481A1 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos.
CL2018003260A1 (es) Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos.
CL2020003008A1 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
CL2021001536A1 (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
BR112022011123A2 (pt) Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112022014949A2 (pt) Compostos e usos dos mesmos
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
BR112017003231A2 (pt) compostos heterobicíclicos e seu uso para o tratamento da tuberculose
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1